Haemonetics Acquires Vivasure Medical for up to €185M, Expanding Percutaneous Vessel Closure Portfolio

summarizeSummary

Haemonetics Corporation announced the acquisition of Vivasure Medical Limited for an upfront payment of €100 million and up to €85 million in contingent consideration, enhancing its presence in the large-bore closure market.

check_boxKey Events

• Acquisition of Vivasure Medical

  Haemonetics Corporation acquired Vivasure Medical Limited, a company specializing in next-generation percutaneous vessel closure technology.

• Transaction Value

  The deal includes an upfront cash payment of €100 million (approximately €52 million net of prior investments) and up to an additional €85 million in contingent consideration based on performance milestones.

• Strategic Expansion

  This acquisition expands Haemonetics' complete range of closure devices, bolstering its presence in the large-bore closure market and its impact in fast-growing structural heart and endovascular procedures.

• Financing Method

  The transaction was financed through Haemonetics' available cash on hand, avoiding additional debt or equity dilution.

auto_awesomeAnalysis

This acquisition is a strategic move for Haemonetics, significantly expanding its portfolio of closure devices with Vivasure's next-generation PerQseal Elite system. The technology, which has received CE Mark approval and has an FDA Premarket Approval application pending, positions Haemonetics for increased leadership in fast-growing structural heart and endovascular procedures. Financing the transaction with available cash on hand is a positive signal, indicating strong financial health and avoiding dilution. The contingent consideration structure aligns incentives for Vivasure's future performance.